144 related articles for article (PubMed ID: 37633350)
21. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
22. Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series.
Dasari S; Komiya T
Asian Pac J Cancer Prev; 2022 Jan; 23(1):217-220. PubMed ID: 35092391
[TBL] [Abstract][Full Text] [Related]
23. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer.
Schmid S; Garcia M; Cheng S; Zhan L; Chotai S; Balaratnam K; Khan K; Patel D; Catherine Brown M; Sachdeva R; Xu W; Shepherd FA; Sacher A; Leighl NB; Bradbury P; Moriarty P; Sara Kuruvilla M; Liu G
Lung Cancer; 2022 Apr; 166():58-62. PubMed ID: 35183992
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.
Vavala T; Malapelle U; Veggiani C; Ludovini V; Papotti M; Leone A; Graziano P; Minari R; Bono F; Sapino A; Manotti L; Troncone G; Pisapia P; Girlando S; Buffoni L; Righi L; Colantonio I; Bertetto O; Novello S
J Clin Pathol; 2022 Apr; 75(4):234-240. PubMed ID: 33509945
[TBL] [Abstract][Full Text] [Related]
25. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
26. The role of biomarkers in stage III non-small cell lung cancer.
Rosell R; González-Cao M; Ito M; Santarpia M; Aguilar A; Codony-Servat J
Expert Rev Respir Med; 2023; 17(6):469-480. PubMed ID: 37317885
[TBL] [Abstract][Full Text] [Related]
27. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
[TBL] [Abstract][Full Text] [Related]
28. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
[TBL] [Abstract][Full Text] [Related]
29. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
Peled N; Roisman LC; Levison E; Dudnik J; Chernomordikov E; Heching N; Dudnik E; Keren-Rosenberg S; Nechushtan H; Salhab A; Hershkovitz D; Tsuriel S; Hannes V; Rotem O; Lazarev I; Lichtenberg R; Granot IS; Krayim B; Shalata W; Levin D; Krutman Y; Allen AM; Blumenfeld P; Lavrenkov K; Kian W
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):105-114. PubMed ID: 36925073
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE
Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656
[TBL] [Abstract][Full Text] [Related]
32. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
[TBL] [Abstract][Full Text] [Related]
33. Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial.
Ko JJ; Banerji S; Blais N; Brade A; Clelland C; Schellenberg D; Snow S; Wheatley-Price P; Yuan R; Melosky B
Curr Oncol; 2023 Mar; 30(4):3817-3828. PubMed ID: 37185402
[TBL] [Abstract][Full Text] [Related]
34. Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.
Evison M; Edwards J; McDonald F; Popat S
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):527-536. PubMed ID: 32216979
[TBL] [Abstract][Full Text] [Related]
35. Perioperative targeted therapy for oncogene-driven NSCLC.
Liu SY; Zhang JT; Zeng KH; Wu YL
Lung Cancer; 2022 Oct; 172():160-169. PubMed ID: 35644704
[TBL] [Abstract][Full Text] [Related]
36. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
38. Treatment Decision Drivers in Stage III Non-Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States.
Cotarla I; Boron ML; Cullen SL; Spinner DS; Faulkner EC; Carroll MC; Shah S; Yagui-Beltran A
JCO Oncol Pract; 2020 Oct; 16(10):e1232-e1242. PubMed ID: 32552457
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Cortiula F; Reymen B; Peters S; Van Mol P; Wauters E; Vansteenkiste J; De Ruysscher D; Hendriks LEL
Ann Oncol; 2022 Sep; 33(9):893-908. PubMed ID: 35777706
[TBL] [Abstract][Full Text] [Related]
40. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
